# Phase I-II PTCy, Bortezomib and Sitagliptin for Prevention of GvHD Following Allogeneic HSCT

> **NCT07675174** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Northwell Health** · enrollment: 72 (estimated)

## Conditions studied

- GVHD - Graft-Versus-Host Disease

## Interventions

- **DRUG:** Post transplant cyclophosphamide, bortezomib and sitagliptin in 3+3 design to MTD

## Key facts

- **NCT ID:** NCT07675174
- **Lead sponsor:** Northwell Health
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07-01
- **Primary completion:** 2030-07-01
- **Final completion:** 2032-07-01
- **Target enrollment:** 72 (ESTIMATED)
- **Last updated:** 2026-06-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07675174

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07675174, "Phase I-II PTCy, Bortezomib and Sitagliptin for Prevention of GvHD Following Allogeneic HSCT". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07675174. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*